Peptides in Melanoma Therapy

Mocellin, Simone

doi:10.2174/138161212799277734

Cited by 3 publications

(1 citation statement)

References 139 publications

(149 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…With the steadily increasing number of known pathogen and cancer-derived epitopes comes great potential for the use of synthetic peptides for vaccination and immunotherapy. Peptide-based immunotherapy has been most commonly explored in the treatment of various forms of cancer (7–10), since the early identification of the MAGE peptide by Boon and colleagues (11). Synthetic peptides have significant advantages over other vaccine modalities, including minimal toxicity, chemical stability, indefinite storage and easy characterization for purity and composition using well-established technology (reviewed in (12)).…”

Section: Introductionmentioning

confidence: 99%

Orchestration of CD4 T Cell Epitope Preferences after Multipeptide Immunization

Tung

Sant

2013

The Journal of Immunology

View full text Add to dashboard Cite

A detailed understanding of the molecular and cellular mechanisms that underlie epitope preferences in T cell priming is important for vaccines designed to elicit a broad T cell response. Protein vaccinations generally elicit CD4 T cell responses that are skewed toward a small fraction of epitopes, a phenomenon known as immunodominance. This characteristic of T cell responses, that limits the diversity of CD4 T cell recognition, is generally attributed to intracellular antigen processing. However, we recently discovered that immunodominance hierarchies persist even after vaccination with synthetic peptides. In this study, we probed the regulatory mechanisms that cause diminished CD4 T cell responses to subdominant peptides after such multi-peptide immunization in mice. We have found that the delivery of subdominant and dominant epitopes on separate dendritic cells rescues expansion of less favored CD4 T cells. Furthermore, through the use of genetic models and inhibitors, we have found that selective losses in CD4 T cell responses are mediated by an IFN-γ-induced pathway, involving indoleamine 2,3-dioxygenase (IDO), and that regulatory T cell (Treg) activities may also regulate preferences in CD4 T cell specificity. We propose that after multi-peptide immunization, the expansion and differentiation of dominant T cells initiate complex regulatory events that determine the final peptide specificity of the elicited CD4 T cell response.

show abstract